Evoke Pharma PE Ratio 2012-2025 | EVOK
Current and historical p/e ratio for Evoke Pharma (EVOK) from 2012 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Evoke Pharma PE ratio as of September 17, 2026 is 0.00.
| Evoke Pharma PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-02-27 | 29.90 | 0.00 | |
| 2025-09-30 | 4.97 | $-0.43 | 0.00 |
| 2025-06-30 | 2.60 | $-0.92 | 0.00 |
| 2025-03-31 | 2.75 | $-1.23 | 0.00 |
| 2024-12-31 | 4.42 | $-2.81 | 0.00 |
| 2024-09-30 | 4.76 | $-11.10 | 0.00 |
| 2024-06-30 | 6.35 | $-16.24 | 0.00 |
| 2024-03-31 | 7.32 | $-22.02 | 0.00 |
| 2023-12-31 | 12.60 | $-27.97 | 0.00 |
| 2023-09-30 | 16.56 | $-26.96 | 0.00 |
| 2023-06-30 | 19.80 | $-28.08 | 0.00 |
| 2023-03-31 | 22.80 | $-29.89 | 0.00 |
| 2022-12-31 | 32.16 | $-31.45 | 0.00 |
| 2022-09-30 | 22.44 | $-33.01 | 0.00 |
| 2022-06-30 | 38.88 | $-34.57 | 0.00 |
| 2022-03-31 | 71.28 | $-36.25 | 0.00 |
| 2021-12-31 | 79.20 | $-38.18 | 0.00 |
| 2021-09-30 | 187.20 | $-43.47 | 0.00 |
| 2021-06-30 | 197.28 | $-46.23 | 0.00 |
| 2021-03-31 | 263.52 | $-76.38 | 0.00 |
| 2020-12-31 | 371.52 | $-74.94 | 0.00 |
| 2020-09-30 | 675.36 | $-69.18 | 0.00 |
| 2020-06-30 | 509.76 | $-67.73 | 0.00 |
| 2020-03-31 | 167.04 | $-40.35 | 0.00 |
| 2019-12-31 | 233.28 | $-46.12 | 0.00 |
| 2019-09-30 | 123.84 | $-53.32 | 0.00 |
| 2019-06-30 | 90.00 | $-56.21 | 0.00 |
| 2019-03-31 | 216.00 | $-63.41 | 0.00 |
| 2018-12-31 | 357.12 | $-66.29 | 0.00 |
| 2018-09-30 | 429.12 | $-60.53 | 0.00 |
| 2018-06-30 | 360.00 | $-96.56 | 0.00 |
| 2018-03-31 | 299.52 | $-95.12 | 0.00 |
| 2017-12-31 | 325.44 | $-129.70 | 0.00 |
| 2017-09-30 | 480.96 | $-121.06 | 0.00 |
| 2017-06-30 | 368.44 | $-113.85 | 0.00 |
| 2017-03-31 | 446.40 | $-154.20 | 0.00 |
| 2016-12-31 | 290.88 | $-165.73 | 0.00 |
| 2016-09-30 | 325.44 | $-216.17 | 0.00 |
| 2016-06-30 | 986.40 | $-234.91 | 0.00 |
| 2016-03-31 | 732.96 | $-250.76 | 0.00 |
| 2015-12-31 | 475.20 | $-269.50 | 0.00 |
| 2015-09-30 | 419.04 | $-289.67 | 0.00 |
| 2015-06-30 | 753.12 | $-319.94 | 0.00 |
| 2015-03-31 | 1015.20 | $-330.02 | 0.00 |
| 2014-12-31 | 849.60 | $-317.05 | 0.00 |
| 2014-09-30 | 791.93 | $-266.61 | 0.00 |
| 2014-06-30 | 1164.96 | $-234.91 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |